Press Releases
The Association for Accessible Medicines and its Biosimilars Council applaud CMS’s November 6 proposal to allow Medicare Part D plans… Read more »
Washington, D.C. (February 21, 2023) – The Biosimilars Council released the following statement in response to the new Matrix Global… Read more »
WASHINGTON, DC – (June 17, 2021) AAM and its Biosimilars Council welcome today’s decision by the U.S. Supreme Court in… Read more »
Congress’ Bipartisan Efforts to Increase Patient Access to Biosimilars Respond to America’s Drug Pricing Crisis WASHINGTON, DC (OCTOBER 2, 2019)… Read more »
Delayed Adoption of Biosimilars Has Cost America’s Health Care System $2.2 Billion Since 2015 WASHINGTON, DC (SEPTEMBER 9, 2019) —… Read more »
Delayed Access to Biosimilars Has Cost the U.S. Health Care System $7.6 Billion Since 2015 BIOSIMILARS COUNCIL | June 25,… Read more »
WASHINGTON, DC (May 30, 2019) — UnitedHealthcare’s (UHC) recent announcement that it will begin preferring brand name biologics over lower… Read more »
WASHINGTON, DC (May 17, 2019) — “We commend CMS for its work to promote greater utilization of lower-cost generic and… Read more »
WASHINGTON, DC (Nov. 28, 2017) – The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), released a national poll today showing support for congressional action to lower out-of-pocket costs for patients and reduce federal […]
The Association for Accessible Medicines (AAM) and its Biosimilars Council praise the Centers for Medicare & Medicaid Services (CMS) decision to revise its current biosimilars reimbursement policyin Medicare Part B, as part of the Revisions to Payment Policies under the […]
WASHINGTON, DC (October 4, 2017) — The Association for Accessible Medicines (AAM) announced today that Boehringer Ingelheim Pharmaceuticals, Inc. has joined its Biosimilars Council. Molly Burich, Boehringer Ingelheim’s Associate Director for Public Policy{…}
Today, the Association for Accessible Medicines (AAM) and its Biosimilars Council released an analysis finding that if the Centers for Medicare & Medicaid Services (CMS) were to revise its current reimbursement policy for biosimilar medicines […]
Today, the Association for Accessible Medicines (AAM) and its Biosimilars Council announced the results of a new patient access study, “Biosimilars in the United States: Providing More Patients Greater Access to Lifesaving Medicines.” […]
To ensure patients have access to more affordable versions of expensive biologic medicines, the Biosimilars Council today urged the Centers for Medicare and Medicaid Services (CMS) to revise its reimbursement policy for biosimilars […]
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), formerly the Generic Pharmaceutical Association, urges the Supreme Court to recognize that biosimilar medicines can generate billions […]
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), formerly the Generic Pharmaceutical Association, urges the Supreme Court to recognize that biosimilar medicines can generate billions […]
“I am David Gaugh, Senior Vice President of Sciences and Regulatory Affairs at the Generic Pharmaceutical Association (GPhA) and the Biosimilars Council (Council) and a licensed pharmacist.[…]